pharma news today obesity glp-1 A diabetes drug. Then a weight-loss drug. Then a global blockbuster. Here's how GLP-1s went from helping manage blood sugar to becoming one of medicine's biggest stories. [GLP-1, Ozempic, Wegovy, Mounjaro, diabetes Obesity Deep Dive: How Payer

Of those 161 patients, 16 (10%) experienced recurrent acute pancreatitis after GLP-1 receptor agonist therapy (mean duration 10.8 7.2 months): 6 (38%) were caused by the GLP-1 receptor agonist (as clinically determined by the treating medical team), three (18%) were due to hypertriglyceridemia, two (12%) due to alcohol use, one (6%) due to another oral hypoglycemic agent, one (6%) due to ampulla stenosis, and three (19%) were idiopathic

Evidence supporting combined therapy is emerging but remains limited as a recent meta-analysis of randomized controlled trials reported lower risk of HF hospitalization with concomitant SGLT2 inhibitor and GLP-1 receptor agonist therapy compared with monotherapy or standard care [24]

Injure-Repair process Fibrosis is characterized by excessive deposition of ECM components and represents a maladaptive response to chronic or repeated tissue injury [29, 30]

GlyNAC in food isnt a formal nutrient, but the logic behind it is real